In addition to that ccRCC patients with different clinical features had higher levels of MAP3K8 expression than the normal, we found that patients with ccB (P = 8.77E-4) and tumor grade 4 (P = 2.42E-2) subtypes expressed more MAP3K8 than that with ccA and tumor grade 3, respectively. This evidence concerns the gene FBN2 and nonpapillary renal cell carcinoma.